Skip to content
  • Home
  • Book Bag: 0 items (Full)
    • English
    • 日本語
    • 中文(简体)
    • 中文(繁體)
    • اللغة العربية
  • About
Advanced
  • Pembrolizumab 400 mg every 6 w...
  • Cite this
  • Text this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Add to Book Bag Remove from Book Bag
  • Permanent link

Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study

Show other versions (1)
Bibliographic Details
Published in:PLoS ONE
Main Authors: Graham Cohen, Bernardo Rapoport, Sze W. Chan, Paul Ruff, Ana Arance, Karmele Mujika Eizmendi, Baerin Houghton, Michael P. Brown, Robert M. Zielinski, Eva Muñoz Couselo, Megan Lyle, James R. Anderson, Lokesh Jain, Dinesh de Alwis, Mallika Lala, Omobolaji Akala, Elliot Chartash, Conrad Jacobs
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2024-01-01
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556718/?tool=EBI
  • Holdings
  • Description
  • Other Versions (1)
  • Similar Items
  • Staff View

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556718/?tool=EBI

Similar Items

  • Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study.
    by: Graham Cohen, et al.
    Published: (2024-01-01)
  • Keynotes
    Published: (2025-05-01)
  • Keynotes
    Published: (2023-05-01)
  • Inappropriate Prescribing of Cefixime 400 mg Every 12 Hours Dose
    by: Durr-e-Shahwar Siddiqui
    Published: (2023-06-01)
  • Keynote Addresses
    by: Marie Bilodeau
    Published: (2019-12-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs